Sign inJoin waitlistJoin the waitlist

Bouthaina Dabaja

Section Chief · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2003–2005
Radiation Oncology
University of Texas M D Anderson Cancer Center
1999–2003
University of Texas M D Anderson Cancer Center
1997–1999
American University of Beirut-Faculty of Medicine
1993–1996
American University of Beirut-Faculty of Medicine
1990–1993
Doctor of Medicine
1987–1991

Research

Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients
Cancer · 2004 · First of 5 authors · 391 citations
Double hit lymphoma: the MD Anderson Cancer Center clinical experience
British Journal of Haematology · 2014 · 309 citations
Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group
International journal of radiation oncology · 2014 · 245 citations

Chelsea Pinnix
109 papers · 2 as a resident
Jillian Gunther
72 papers · 17 as a resident
Sarah Milgrom
65 papers · 3 as a resident
Loretta Nastoupil
42 papers · 5 as a fellow
Luis Fayad
38 papers
YO
Yasuhiro Oki
38 papers
Sattva Neelapu
36 papers
Jeffrey Medeiros
35 papers
Jason Westin
34 papers
MF
Michelle Fanale
33 papers
NF
Nathan Fowler
32 papers
Sairah Ahmed
31 papers

Clinical trials

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2022–2027
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
Principal investigator · Active not recruiting · Early phase 1
M.D. Anderson Cancer Center
2021–2028
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Principal investigator · Recruiting
M.D. Anderson Cancer Center
2020–2026
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2019–2027